REG - BSF Enterprise PLC - Further Investment and Appointment of Adviser

BSF EnterpriseAnnouncement

Today 15:15

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20260402:nRSB3150Za&default-theme=true

RNS Number : 3150Z  BSF Enterprise PLC  02 April 2026

2 April 2026

BSF Enterprise PLC

 

Further Investment and Appointment of Adviser

 

 

BSF Enterprise PLC (LSE: BSFA) ("BSF" or the "Company"), a leading innovator
in tissue-engineered materials, is pleased to announce that it has placed
38,500,000 new ordinary shares in the Company ("Placing Shares") raising
£385,000 before expenses at 1p per share in a placing ("Placing") utilising
the Company's total available headroom without further authority from
shareholders.

 

In light of the exciting news on the unveiling of our T-Rex leather Handbag
the Placing was arranged within our present headroom. This fundraise was
supported by a single strategic investor to reinforce the Company's strategic
business and growth plans, with the possibility of significant growth in
shareholder value throughout 2026.

 

Appointment of Financial Adviser and Broker

 

BSF is pleased to announce that it has appointed Bowsprit Partners Limited
("Bowsprit Partners") as its Financial Adviser and Broker with immediate
effect.

 

Bowsprit Partners is a London-based corporate finance and corporate broking
firm specialising in advising both public and private companies. Bowsprit
Partners is a Member Firm of the London Stock Exchange and holds multiple
accreditations including Listing Sponsor status for the Euronext Growth and
Access Markets in Paris, Brussels, Lisbon and Dublin, Euronext Growth Advisor
for Euronext Growth Oslo, Corporate Adviser for the Aquis Stock Exchange,
Certified Adviser for the Nasdaq First North Growth Market in Stockholm and US
OTC Markets Sponsor permission for international companies.

 

Issue of Warrants

 

For every Placing Share issued pursuant to the Placing, investors will receive
1 warrant allowing the holder to subscribe for an additional Ordinary Share in
the Company at an exercise price of 1.5p per Ordinary Share, exercisable
within 3 years of Admission ("Investor Warrants"). In aggregate 38,500,000
Warrants have been issued pursuant to the Placing.

 

In connection with the Placing, the Company will issue, on completion of the
Placing, 23,100 warrants to Bowsprit Partners who arranged the Placing
("Broker Warrants"). The Broker Warrants shall be exercisable at 1p per
Ordinary Share. The Broker Warrants are exercisable at any time within three
years of Admission.

 

Any issuance of shares under the Investor Warrants or Broker Warrants will be
subject to available authority to issue shares being granted by the Company's
shareholders in due course.

 

Admission

 

Completion of the Placing is conditional on, inter alia, the Placing Shares
being admitted to listing on the Equity Shares (transition) category of the
Official List and to trading on the London Stock Exchange's main market for
listed securities ("Admission").

 

Applications will be made to the FCA and to the London Stock Exchange for
Admission in respect of all the Placing Shares proposed to be issued on
completion of the Placing. It is expected that Admission will become
effective, and that dealings in the Placing Shares are expected to commence on
or around 8.00 a.m. on or around 15 April 2026.

 

The rights attaching to the Placing Shares will rank pari passu with the
existing ordinary shares of the Company.

 

 

Total Voting Rights

 

Following Admission, the Company's enlarged share capital will comprise
166,874,437 ordinary shares of 1 penny each. Therefore, the total number of
voting rights in the Company will be 166,874,437. This figure may be used by
shareholders as the denominator for calculations by which they will determine
if they are required to notify their interest in the Company, or a change to
their interest in the Company, under the Financial Conduct Authority's
Disclosure Guidance and Transparency Rules.

 

This announcement contains inside information for the purposes of Article 7 of
Regulation 2014/596/EU which is part of domestic UK law pursuant to the Market
Abuse (Amendment) (EU Exit) regulations (SI 2019/310).

 

END

 

Engage with the BSF Enterprise management team directly by asking questions,
watching video
summaries and seeing what other shareholders have to say. Navigate to our
Interactive Investor
website here:

 

https://bsfenterprise.com/link/eNwpdr (https://bsfenterprise.com/link/eNwpdr)

 

For further enquiries, please visit www.bsfenterprise.com
(http://www.bsfenterprise.com) or contact:

 

 BSF Enterprise PLC                                                           https://bsfenterprise.com/s/a1f22b (https://bsfenterprise.com/s/a1f22b)

 Geoff Baker - Chairman

 Che Connon - CEO & Director

 We encourage all investors to share questions on this announcement via our
 investor website.
 Bowsprit Partners

 John Treacy                                                                   +44 (0)203 883 4430

 James Sheehan
 ISIN of the Ordinary Shares

 is GB00BHNBDQ51.

 SEDOL Code is BHNBDQ5.

 

 

 

Subscribe to our news alert service: https://bsfenterprise.com/s/bb9f43
(https://bsfenterprise.com/s/bb9f43)

 

About BSF Enterprise PLC

BSF Enterprise PLC (LSE:BSFA) develops and commercialises cutting-edge
tissue-engineered solutions, including lab-grown leather (via LGL), cultivated
meat, and corneal repair technologies. By leveraging its proprietary
scaffold-free ATEP™ platform, BSF delivers sustainable, high-performance
alternatives to conventional materials, targeting global markets where
provenance, ethics, and performance are increasingly prized by consumers and
brands alike.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  IOESSEFLEEMSESL



            Copyright 2019 Regulatory News Service, all rights reserved